

To: [redacted] [redacted] [redacted]@rivm.nl
From: [redacted]
Sent: Wed 1/6/2021 5:40:59 PM
Subject: RE: slide consortia RG vaccinatie
Received: Wed 1/6/2021 5:41:00 PM

Super, dank je!

Van: [redacted] <[redacted]@rivm.nl>
Datum: 6 januari 2021 om 18:26:48 CET
Aan: [redacted] <[redacted]@rivm.nl>
Onderwerp: RE: slide consortia RG vaccinatie

Hoi [redacted]
 Bijgaand de contactpersonen van Target to B, VOICE en RECOVAC.
 De anderen kent [redacted] (PRIDE: [redacted])
 Groet [redacted]

[redacted]
 Centre for Immunology of Infectious Diseases and Vaccines | National Institute for Public Health and the Environment (RIVM) | Antonie van Leeuwenhoeklaan 9 | PO
 5.1.2e 8720 BA BILTHOVEN | The Netherlands

UTRECHT | The Netherlands
 T: +31 (0) [redacted] | M: +31 (0) [redacted] | E: [redacted]@rivm.nl

From: [redacted] <[redacted]@rivm.nl>
Sent: woensdag 6 januari 2021 17:23
To: [redacted] <[redacted]@rivm.nl>
Subject: FW: slide consortia RG vaccinatie

Hi [redacted]

Weet jij heel toevallig 1 naam en 1 ziekenhuis per consortium uit onderstaande slide?

COVID-19 Vaccinatie van risicogroepen: trial consortia*

Naam	Risicogroep
Target2be	Patiënten met auto-immuunziekten en niet-aangeboren immuundeficiënties
VOICE	Oncologie patiënten
RECOVAC	Niertransplantatie- en terminaal nierfalen patiënten
COVALENT	Longtransplantatie patiënten
VACOPIID	Patiënten met aangeboren / primaire immuundeficiënties
PRIDE	Mensen met Syndroom van Down

* voor zover bekend

Dan zet ik die er snel nog even bij.
 Alvast dankjewel!

Met vriendelijke groet,

[redacted]
T 06 [redacted]

From: [redacted] <[redacted]@rivm.nl>
Sent: woensdag 6 januari 2021 17:05
To: [redacted] <[redacted]@rivm.nl>

Subject: RE: slide consortia RG vaccinatie

Hi 5.1.2e

Mooie slide maar wellicht de PI en ziekenhuis van PI erbij zetten?

Willen ze vast weten 5.1.2e

From: 5.1.2e <5.1.2e@rivm.nl>
Sent: woensdag 6 januari 2021 12:17
To: 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>
Subject: slide consortia RG vaccinatie

Hoi,

Zoals beloofd in # een (simpele) slide met trial consortia mbt risicogroepen vaccinatie voor zover nu bij mij bekend...
 5.1.2e mocht jij er meer weten, wil je dan ajb aanvullen?

Dit is ter backup, mocht er morgenavond om gevraagd worden.

Gezien de actualiteit van de 1 dosis-discussie heb ik nu geen overzicht gemaakt van 1D-effectiviteit.

Met vriendelijke groet,

5.1.2e
T 06 5.1.2e

From: 5.1.2e <5.1.2e@rivm.nl>
Sent: maandag 4 januari 2021 11:14
To: 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>; 5.1.2e <5.1.2e@rivm.nl>
Subject: FW: Statement on first dose prioritisation JCVI en berekeningen

Hi,

Wie weet weten jullie dit al en wellicht ten overvloede. Ik kreeg deze van 5.1.2e nav onze discussie hierover. (zie link in mail 5.1.2e 2 januari)

NB: Je ziet de hoge bescherming ook al in de figuur van het artikel in de NEJM over het Pfizer vaccin en dat de 50% na 1 vaccinatie erg artificieel is. Het is duidelijk dat na die eerste weken je op 80-90% bescherming komt, alleen op dag 19 is het 50%. UK wil op den duur wel voor 2 vaccinaties, maar later na een langer interval. Idem Quebec.

5.1.2e

From: 5.1.2e <5.1.2e@rivm.nl>
Sent: zondag 3 januari 2021 14:02
To: 5.1.2e <5.1.2e@rivm.nl>
Subject: FW: Statement on first dose prioritisation

Hoi 5.1.2e

UK gaat ook 1 dose geven en tweede dose max 12 weken later.
 Dan kunnen we nu meer personen met 1 dose gevaccineerd worden.
 De berekeningen van VE zijn nu anders omdat de cases in de eerste week na vaccinatie eruit zijn gehaald.
 Dan is VE nagenoeg gelijk aan 2 doses.

Ik neem aan dat deze info bij onze collega's al bekend is, zo niet, wil jij doorsturen?

5.1.2e

From: 5.1.2e (Respiratory Medicine) <5.1.2e @nuh.nhs.uk>
Sent: zaterdag 2 januari 2021 23:50
To: 5.1.2e <5.1.2e @phc.ox.ac.uk>
Cc: 5.1.2e <5.1.2e @phe.gov.uk>; 5.1.2e <5.1.2e @bristol.ac.uk>; 5.1.2e @ftcon.co.uk;
5.1.2e @wales.nhs.uk; 5.1.2e @lshtm.ac.uk'; 5.1.2e @rivm.nl'; 5.1.2e
<5.1.2e @ucl.ac.uk>; 5.1.2e <5.1.2e @hscni.net>; 5.1.2e <5.1.2e @phe.gov.uk>; 5.1.2e
<5.1.2e @nhs.net>; 5.1.2e <5.1.2e @phe.gov.uk>; 5.1.2e <5.1.2e @imperial.ac.uk>;
5.1.2e @nhslothian.scot.nhs.uk; 5.1.2e @warwick.ac.uk'; 5.1.2e @rug.nl; 5.1.2e @nhs.net';
5.1.2e @gmail.com; 5.1.2e @soton.ac.uk'; 5.1.2e <5.1.2e @phe.gov.uk>; 5.1.2e
5.1.2e @uhbristol.nhs.uk>; 5.1.2e <5.1.2e @phe.gov.uk>; 5.1.2e
<5.1.2e @phe.gov.uk>; 5.1.2e e <5.1.2e @phe.gov.uk>; 5.1.2e <5.1.2e @phe.gov.uk>; 5.1.2e
<5.1.2e @phe.gov.uk>; 5.1.2e <5.1.2e @phe.gov.uk> 5.1.2e
<5.1.2e @phe.gov.uk>


Subject: [Spam] RE: Statement on first dose prioritisation

Dear 5.1.2e

For information. Below is the email from RCGP
I have copied other members in so that all are updated.

Best wishes,

5.1.2e



5.1.2e

buiten verzoek

tens of millions of doses by March.

The other issue that is coming up is mixed vaccine schedules which is relatively easy to deal with, and Mary's press release helps.

Bw

5.1.2e

On 2 Jan 2021, at 20:11, 5.1.2e (Respiratory Medicine) <5.1.2e@nuh.nhs.uk> wrote:

Dear JCVI members,

As you will know, since Wednesday, there has been quite a storm relating to our decision to allow the second dose of the Pfizer vaccine to be given up to 12 weeks after the first dose.

This has been energized by 2 factors:

1. The press release by Pfizer re-stating their position, and re-issuing the figure of 52% VE after the first dose
2. The unhappiness, mainly from primary care, regarding the instruction they received to re-assign appointments already made for the second vaccine dose.

On Thursday, Mary and I were at a meeting with the Presidents of the Royal Colleges and the BMA Council Chair, chaired by Stephen Powis. My sense was that everyone at the meeting went away with much greater understanding and agreement of the rationale behind our decision.

On New Year's day, the RCGP emailed a letter to all RCGP members to aid with information dissemination. The email included the Short Statement from JCVI which was released on Thursday evening.

The CMO's CAS Alert on Thursday evening also contains the JCVI Short Statement, and the COVID19 GB chapter. So, it is a good link to share: <https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103132>

To further aid visibility, we are seeking to have the Short Statement published alongside the 30 Dec JCVI Statement on the DHSC website.

Below are news articles regarding US and Canadian responses to the UK position. Looks like both points of view being debated.

<https://www.businessinsider.com/expert-reaction-uk-untested-vaccination-strategy-single-dose-pfizer-2020-12?r=US&IR=T>

<https://www.theglobeandmail.com/canada/article-new-data-favour-administering-covid-19-vaccines-as-fast-as-possible/>

It is understandable that the US policy team are defending their current position on the dose interval for the Pfizer vaccine. The UK's move will have put pressure on them. **We have had the advantage of seeing the latest analyses from the AZ trials which provide some evidence supporting a good first dose effect lasting to 12 weeks.** There is no strong reason to believe that the Pfizer vaccine would provide *less* protective immunity.

All your efforts in communicating the rationale behind the JCVI advice is much appreciated. Please continue to share the Short Statement as appropriate. Whilst clinical trials of a 2-dose extended interval schedule are unlikely in the near future, we will obtain non-randomised data from post-implementation surveillance of vaccine effectiveness (and the UK is uniquely placed to gather such data).

Best wishes,

5.1.2e

From: 5.1.2e [5.1.2e @phe.gov.uk]
Sent: 31 December 2020 17:52
To: 5.1.2e; 5.1.2e @ftcon.co.uk; 5.1.2e @wales.nhs.uk; 5.1.2e; 5.1.2e @lshtm.ac.uk; 5.1.2e @rivm.nl; 5.1.2e; 5.1.2e; 5.1.2e; 5.1.2e; 5.1.2e; 5.1.2e (Respiratory Medicine); 5.1.2e @nhslothian.scot.nhs.uk; 5.1.2e @warwick.ac.uk; 5.1.2e @rug.nl; 5.1.2e @nhs.net; 5.1.2e @gmail.com; 5.1.2e @soton.ac.uk; 5.1.2e; 5.1.2e
Cc: 5.1.2e; 5.1.2e; 5.1.2e e; 5.1.2e; Jcvi; 5.1.2e; PHE-Pressoffice; 5.1.2e
Subject: RE: Statement on first dose prioritisation

Slightly revised version attached

5.1.2e

5.1.2e

5.1.2e

Immunisation Service
National Infection Service
Public Health England
Email: 5.1.2e @phe.gov.uk
Tel: 020 5.1.2e
www.gov.uk/phe Follow us on Twitter @ 5.1.2e
Protecting and improving the nation's health

From: 5.1.2e
Sent: 31 December 2020 17:49
To: 5.1.2e <5.1.2e @bristol.ac.uk>; 5.1.2e @ftcon.co.uk; 5.1.2e @wales.nhs.uk; 5.1.2e <5.1.2e @phc.ox.ac.uk>; 5.1.2e @lshtm.ac.uk; 5.1.2e @rivm.nl; 5.1.2e <5.1.2e @ucl.ac.uk>; 5.1.2e <5.1.2e @hscni.net>; 5.1.2e @phe.gov.uk; 5.1.2e @nhs.net; 5.1.2e <5.1.2e @phe.gov.uk>; 5.1.2e <5.1.2e @imperial.ac.uk>; 5.1.2e <5.1.2e @nuh.nhs.uk>; 5.1.2e @nhslothian.scot.nhs.uk; 5.1.2e @warwick.ac.uk; 5.1.2e @rug.nl; 5.1.2e @nhs.net; 5.1.2e @gmail.com; 5.1.2e @soton.ac.uk; 5.1.2e <5.1.2e @phe.gov.uk>; 5.1.2e <5.1.2e @UHBristol.nhs.uk>
Cc: 5.1.2e <5.1.2e @phe.gov.uk>; 5.1.2e <5.1.2e @phe.gov.uk>; 5.1.2e <5.1.2e @phe.gov.uk>; Jcvi <5.1.2e @phe.gov.uk>
Subject: Statement on first dose prioritisation

Dear JCVI Members

We have had to quickly put together a short statement on JCVI considerations on the interval between doses, given a substantial amount of interest in this overnight with some criticism from some quarters.

I attach the statement, which was agreed with the Chair, and is now available on the JCVI website alongside meeting minutes. [Minutes | Powered by Box](#)

Kind regards
Andy

5.1.2e

5.1.2e

Immunisation Service
National Infection Service
Public Health England
Email: [redacted]@phe.gov.uk
Tel: 02 [redacted]
www.gov.uk/phe Follow us on Twitter @ [redacted]
Protecting and improving the nation's health

*** The information contained in the Email and any attachments is confidential and intended solely and for the attention and use of the named addressee(s). It may not be disclosed to any other person without the express authority of the PHE, or the intended recipient or both. If you are not the intended recipient, you must not disclose, copy, distribute or retain this message or any part of it. This footnote also confirms that this Email has been swept for computer viruses by Exchange Online Protection, but please re-sweep any attachments before opening or saving. [HTTP://www.phe.gov.uk](http://www.phe.gov.uk)

The information contained in this email may be the subject of public disclosure under the Freedom of Information Act 2000 - unless legally exempt from disclosure, the confidentiality of this email and your reply cannot be guaranteed.

Copyright of this email and any attachments created by us remains vested in the Nottingham University Hospitals NHS Trust.

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed.

This footnote also confirms that this email message has been swept by anti-virus software for the presence of known computer viruses.

Nottingham University Hospitals NHS Trust
City Hospital campus | Hucknall Road | Nottingham | NG5 1PB | Tel: 0115 969 1169
QMC campus | Derby Road | Nottingham | NG7 2UH | Tel: 0115 924 9924

If you have received this email in error please notify the sender.

Tracking ID: D50B1062-B7F0-7505-8F77-0B29BB0B7879 - Sat Jan 2 20:11:07 2021

If you have received this email in error please notify the sender.

Tracking ID: 471EBB7B-B7F2-AE05-BDD6-C1C08FEA96EE - Sat Jan 2 22:50:14 2021